PipelineReview.com3h
GIOSTAR Announces FDA Clearance of the IND for Starting PHASE-2 Clinical Trial for Developing Specific Stem Cell Therapy for Type II Diabetes.
SAN DIEGO, CA, USA I November 13, 2024 I Global Institute of Stem Cell Therapy and Research, Inc. known as GIOSTAR, a San Diego, California based Global organization at the forefront of stem cell ...
PipelineReview.com3h
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
NEW YORK, NY, USA I November 13, 2024 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the ...
PipelineReview.com3h
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis
BETHESDA, MD & GAITHERSBURG, MD, USA I Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new ...
PipelineReview.com3h
BioNTech to Acquire Biotheus to Boost Oncology Strategy
MAINZ, Germany I November 13, 2024 I BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a ...
PipelineReview.com5h
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
ZUG, Switzerland I 13, 2024 I MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating ...
PipelineReview.com5h
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
SOUTH SAN FRANCISCO, CA, USA I 13, 2024 I TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create ...
PipelineReview.com1d
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
DARMSTADT, Germany I 12, 2024 I Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an ...
PipelineReview.com1d
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
SAN DIEGO, CA, USA I November 11, 2024 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines ...
PipelineReview.com1d
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small ...
PipelineReview.com1d
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Collaboration will leverage Flare Therapeutics’ proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules ...
PipelineReview.com2d
STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
CAMBRIDGE, UK I November 11, 2024 I STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it ...
PipelineReview.com2d
Next Generation Gene Therapeutics (NGGT) Announces Positive New Data on NGGT002 for the Treatment of Phenylketonuria (PKU)
NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...